CASI Pharmaceuticals, Inc.

CASIF OTC SEC CIK 1962738
Follow CASI Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$50M−$25M$0$25M$50MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$20.7M−$48.1M
FY24$28.5M−$39.3M
FY23$33.9M−$27M
FY22$38M−$41M
FY21$30M−$36.7M
FY20$15M−$48.3M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400%−200%0%200%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2548.6%−217.3%−232%
FY2439.1%−138.8%−137.6%
FY2359.2%−74%−79.6%
FY2271.7%−89.4%−107.8%
FY2158.7%−138.3%−122.1%
FY2037.6%−351.8%−321.9%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$20.8M
FY24−$29.4M
FY23−$20.2M
FY22−$26.7M
FY21−$35.8M
FY20−$27.4M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • CASI Pharmaceuticals
  • Healthcare median
−400%−300%−200%−100%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearCASI PharmaceuticalsHealthcare median
FY25−232%−30.6%
FY24−137.6%−47%
FY23−79.6%−58%
FY22−107.8%−80.4%
FY21−122.1%−71.9%
FY20−321.9%−62.2%
FY19-−46.3%